MétaCan
Menu
← Retour à la cohorte
Enregistrement W4310109066 · doi:10.1182/blood-2022-169640

Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia

2022· article· en· W4310109066 sur OpenAlexaffabout
Lisa Wang, Erika Wall, Jeffery M. Patterson, Cynthia Wu, Haowei Sun

Notice bibliographique

RevueBlood · 2022
Typearticle
Langueen
DomaineMedicine
ThématiquePlatelet Disorders and Treatments
Établissements canadiensUniversity of Alberta HospitalAlberta Hospital EdmontonUniversity of Alberta
Organismes subventionnairesnon disponible
Mots-clésImmune thrombocytopeniaMedicineVenous thromboembolismImmunologyThrombosisPlateletIntensive care medicineInternal medicine

Résumé

récupéré en direct d'OpenAlex

Background: Adults with chronic immune thrombocytopenia (ITP) have increased risk of arterial thromboembolism (TE) compared to the general population. Adequate therapy with antiplatelets, anticoagulants or revascularization may be limited by thrombocytopenia and bleeding risk. Few studies have examined the quality of arterial TE management in ITP, and outcomes such as bleeding and cardiovascular deaths. Aims: To examine acute inpatient management and outcomes of arterial TE in relapsed/refractory ITP. Methods: This multicentre retrospective cohort study included all chronic ITP patients ≥18 years who received second-line therapy (2012-2020) in the province of Alberta, Canada. Demographics, ITP disease characteristics, traditional vascular risk factors, and history of TE were collected. We also collected ITP-related thrombotic risk factors including splenectomy status, antiphospholipid antibody syndrome (APS), and use of thrombopoietin receptor agonists (TPO-RA) at the time of TE. The incidence rate was calculated by dividing the number of TE events by the person-years of follow-up since ITP diagnosis. For each TE event, we examined the initial and nadir platelet counts, acute ITP-directed therapy, and quality of TE management (antiplatelets, anticoagulants, revascularization) during hospitalization. We assessed outcomes including 30-day mortality, cardiovascular deaths, and bleeding from TE event to last follow-up or death. Research ethics approval was obtained. Results: During 2713 person-years of follow-up since ITP diagnosis, 46/329 patients (14%) developed a total of 53 incident arterial TE events, 9 of whom also developed venous thromboembolism. TE events included 27 (51%) acute coronary syndromes (ACS), 25 (47%) ischemic strokes or transient ischemic attacks (TIA), and 1 (2%) acute limb ischemia. The incidence rate of arterial TE was 2.0 (95% CI 1.5-2.6) per 100 person-years. The median age at time of arterial TE was 67 years (IQR 61-77), 22 (42%) were men (Table 1). Risk factors for arterial TE included: history of atherosclerotic disease (18; 34%), 3 or more traditional vascular risk factors (17; 32%), post-splenectomy status (23; 43%), concurrent TPO-RA use (16; 30%), and APS (5; 9%). Most (37; 70%) were not on antiplatelets or anticoagulants at presentation. Of these, 7 had interruption or discontinuation of prior antiplatelets/anticoagulants due to bleeding risk, and subsequently developed ischemic stroke/TIA. A platelet count <50 x 109/L was observed in 21 (40%) arterial TE events throughout hospitalization. Acute ITP therapies to maintain platelet >50 x 109/L included: IVIG (9/21; 43%), platelet transfusions (7; 33%), TPO-RA (6; 29%), corticosteroids (4; 19%), and rituximab (4; 19%). Of the 27 ACS events, over half (15; 56%) underwent revascularization with either PCI (5 bare metal stents, 6 drug-eluting stents, 1 catheter-directed thrombolysis) or coronary artery bypass graft (3). Patients with platelet count >50 x 109/L showed a non-significant trend towards higher likelihood of revascularization (10/15, 67%) compared to those with platelet count <50 x 109/L (5/11, 45%; P=0.28). Three patients received neither antiplatelets nor revascularization due to severe thrombocytopenia (<30 x 109/L). Of the 25 stroke/TIA events, 6 (24%) underwent revascularization. Antiplatelet or anticoagulants were not offered in 5 cases, mostly due to thrombocytopenia and/or hemorrhagic transformation. At last follow-up, 26/46 (57%) patients died at a median age of 74 (IQR 64-80) years, from cardiovascular deaths (n=10), other TE (n=2), infection (n=7), bleeding (n=1) and other causes (n=6). The 30-day mortality following TE was 10%. Major bleeding occurred in 6 (11%) individuals, at a median of 18 days (IQR 14-32) after TE. Conclusion: Patients with chronic ITP receive suboptimal management of arterial TE including a lower likelihood of receiving antiplatelet/anticoagulants or revascularization. With the advent of newer lines of ITP therapies including three TPO-RAs and fostamatinib, aggressive ITP control is critical to avoid withholding antiplatelet/anticoagulants, and to reduce the risk of bleeding, recurrent TE, and cardiovascular deaths. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,002
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,116
Score d'incertitude au seuil0,232

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0000,002
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0010,002
Études des sciences et des technologies0,0010,000
Communication savante0,0010,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0010,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,012
Tête enseignante GPT0,243
Écart entre enseignants0,232 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2022
Routes d'admission2
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetPlatelet Disorders and Treatments→Travaux en français237 207→